Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

The move will enable the company to strengthen its foothold in the US and establish its presence in the fast-growing global ...

Key Points High-yield dividend stocks can become an alternative source of income. Here are three stocks, each from a ...

Zydus Lifesciences Ltd enters global biologics CDMO market with acquisition of Agenus Inc.'s manufacturing facilities in the ...

M42 will integrate SOPHiA GENETICS’ MSK-ACCESS® powered with SOPHiA DDM™ technology into its testing infrastructure ...

Two new partnerships enhance QIAGEN’s capabilities to support pharma partner clinical trials with significant expansion of ...

The clinical trial tech companies Medidata and Medable are both taking to the floor of the American Society of Clinical ...

Annual Meeting, multiple companies presented clinical trial data showing their drugs and devices helped patients with pancreatic cancer live longer or improve their ability to respond to treatment.

Desiree Hill wasn’t happy with her job as an oncology nurse — so she quit and reinvented herself as an Atlanta-area mechanic.

Which companies developing cancer drugs are attractive takeover targets? Seeking Alpha analysts offer their picks. Read more here.

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...